report_lead_image_with_gradient.png
Q4 2025

Pharma Biotools VC Trends

Download this Report
To download this report, please complete the form below

PitchBook clients can access the full report via the Research Center on the PitchBook Platform.

Pharma biotools VC rebounds as AI-driven platforms lead 2025 funding

The pharma biotools sector regained momentum in 2025 as venture funding rebounded following three years of contraction, driven by investor appetite for asset-light business models and AI-enabled technologies that support drug discovery and development. Deal value rose modestly for the year and remained stable in Q4, signaling a normalization of activity rather than renewed decline. Investment concentrated heavily in generative AI, quantum computing, microfluidics, and synthetic biology, as companies delivering high-fidelity data generation, automation, and software-like services attracted outsized interest. Major Q4 financings for AI-driven protein design platforms and automation-focused tools underscored how investors are backing the emerging “scientific stack” that connects computational discovery with physical experimentation.

Pharma biotools VC deal activity rebounded in 2025, with deal value reaching $5.7 billion and deal count surging to a record 537—signaling renewed investor confidence after three years of contraction.

M&A activity remained subdued, although Halozyme Therapeutics’ acquisition of Elektrofi for up to $900 million marked the sector’s largest exit since 2021 and highlighted continued demand for technologies embedded in biologics delivery and manufacturing workflows. China also emerged as a key growth market, with deal count rising more than 80% YoY and investment concentrated in AI-driven platforms and enabling infrastructure for next-generation therapeutics. Overall, pharma biotools VC activity is stabilizing as investors prioritize platforms capable of generating high-quality datasets, enabling automation, and accelerating commercialization across the broader biopharma ecosystem.


Table of contents
Quarterly analysis 4
        Key takeaways 4
        VC activity 4
        Key VC deals 7
        VC exit activity 8
        AI themes 9
Pharma biotools VC deal summary 24